GlycoGenesys to Present at the Bio-Europe 2005 Partnering Conference

GlycoGenesys, Inc. (Nasdaq: GLGS), a biotechnology
company, announced today that Frederick E. Pierce, II, VP of Business
Development will make a corporate presentation at the Bio-Europe 2005
Partnering Conference on Wednesday, November 9, 2005 at 12:30 pm CEST
in room #3 at the International Congress Center, Dresden, Germany.

   About GlycoGenesys, Inc.

   GlycoGenesys, Inc. is a biotechnology company focused on
carbohydrate drug development. The Company's drug candidate GCS-100, a
unique compound to treat cancer, has been evaluated in previous
clinical trials at low dose levels in patients with colorectal,
pancreatic and other solid tumors with stable disease and partial
response documented. The Company currently is completing a Phase I
dose escalation trial to evaluate higher dose levels of GCS-100LE, a
low ethanol formulation of GCS- 100, at Sharp Memorial Hospital,
Clinical Oncology Research in San Diego, California and the Arizona
Cancer Center in both Tucson and Scottsdale, Arizona. In addition,
GCS-100LE is being evaluated in a Phase I/II trial for multiple
myeloma at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Further clinical trials are planned for 2005, 2006 and 2007. Further
information is available on GlycoGenesys' web site:
www.glycogenesys.com.

   Safe Harbor Statement

   Any statements contained in this release that relate to future
plans, events or performance are forward-looking statements that
involve risks and uncertainties, including, but not limited to, risks
of product development (such as failure to demonstrate efficacy or
safety), risk related to FDA and other regulatory procedures, market
acceptance risks, the impact of competitive products and pricing, the
results of current and future licensing, joint ventures and other
collaborative relationships, risks relating to raising sufficient
capital to fund the Company's operations, developments regarding
intellectual property rights and litigation, and other risks
identified in the Company's Securities and Exchange Commission
filings. Actual results, events or performance may differ materially.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as the date hereof. The
Company undertakes no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.